{"schemaVersion":"wpf-profile-export-v1","exportedAt":"2026-09-18T15:17:46.339Z","profile":{"slug":"cjc-1295","name":"CJC-1295","aliases":["CJC1295","CJC-1295 DAC","Drug Affinity Complex GRF"],"category":"Long-acting GHRH analog"},"synthesis":{"mechanism":"CJC-1295 is a modified growth-hormone-releasing hormone analog designed to resist enzymatic degradation and, in its drug-affinity-complex form, bind circulating albumin. Early studies show prolonged stimulation of growth hormone and IGF-1, but biomarker elevation is not equivalent to demonstrated clinical benefit.","evidence":"Direct evidence consists mainly of small early-phase pharmacokinetic and pharmacodynamic studies plus analytical and anti-doping work. There is no established regulator-approved therapeutic indication, and literature on other GHRH analogs is contextual only.","safety":"Short-term adverse-event reporting does not establish long-term safety. Persistent GH/IGF-1 stimulation raises unresolved questions about glucose regulation, edema, arthralgia, sleep apnea, neoplasia risk, and other endocrine effects. Marketed products may conflate DAC and non-DAC molecules.","observationalBoundary":"The archive distinguishes CJC-1295 with DAC from products marketed as 'CJC-1295 without DAC' or modified GRF(1-29), and labels broader GHRH literature as contextual.","openQuestions":"Which exact molecular form is being studied or sold? What are the long-term metabolic and endocrine outcomes, clinically meaningful benefits, and risks in adequately powered controlled human trials?"},"completion":{"version":"wpf-profile-v1.0","complete":true,"checks":[{"key":"overview","passed":true,"actual":315,"required":100,"severity":"blocking"},{"key":"evidence_summary","passed":true,"actual":258,"required":100,"severity":"blocking"},{"key":"safety_summary","passed":true,"actual":292,"required":100,"severity":"blocking"},{"key":"archive_boundary","passed":true,"actual":165,"required":75,"severity":"blocking"},{"key":"open_questions","passed":true,"actual":198,"required":75,"severity":"blocking"},{"key":"verified_sources","passed":true,"actual":25,"required":25,"severity":"blocking"},{"key":"reviewed_sources","passed":true,"actual":25,"required":1,"severity":"blocking"},{"key":"chemistry","passed":true,"actual":true,"required":true,"severity":"blocking"},{"key":"regulatory_context","passed":true,"actual":2,"required":2,"severity":"blocking"},{"key":"claims","passed":true,"actual":25,"required":1,"severity":"blocking"},{"key":"claim_traceability","passed":true,"actual":0,"required":0,"severity":"blocking"},{"key":"regulatory_freshness","passed":true,"actual":0,"required":0,"severity":"warning"}],"failures":[]},"chemistry":{"id":"4973a2454b719394bc5c1189e6a3a053","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","molecularFormula":null,"molecularWeight":null,"aminoAcidSequence":null,"smiles":null,"inchi":null,"inchikey":null,"structureImageUrl":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},"evidence":[{"id":"7d0bbf3915cb2ca2c611f21a24803097","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41880199/","evidenceTier":"laboratory","summary":"Marketed as more selective and ostensibly safer alternatives, peptides-including growth hormone secretagogues (e.g., Ipamorelin), growth hormone-releasing hormone analogues (e.g., CJC-1295, Sermorelin), and synthetic fragments (e.g., Frag 176-191, KPV)-are promoted …","authors":"Coutinho LFD, DE Oliveira Neves LF, Camilo RP.","publishingOrg":null,"publicationYear":2026,"doi":"10.23736/S0022-4707.26.17773-1","pubmedId":"41880199","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.23736/s0022-4707.26.17773-1","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":63,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":72,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.23736/S0022-4707.26.17773-1","pmid":"41880199","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"ad52c44ac4882176bfce1b1c6379434d","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41138283/","evidenceTier":"laboratory","summary":"The present study aimed to develop a robust nano-LC quadrupole/orbitrap mass spectrometry (nano-LC-Q/Orbitrap MS) method for both screening and confirmation analyses of GHRH and its synthetic analogs (sermorelin/CJC-1293, tesamorelin, and CJC-1295) and the primary m …","authors":"Uçaktürk E, Nemutlu E.","publishingOrg":null,"publicationYear":2026,"doi":"10.1016/j.jpba.2025.117207","pubmedId":"41138283","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.jpba.2025.117207","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1016/j.jpba.2025.117207","pmid":"41138283","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"71bb74b360621244e8bddde3eeb0e985","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41476424/","evidenceTier":"laboratory","summary":"Key peptides evaluated included BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu. RESULTS: BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. ...TB-4 and its derivativ …","authors":"Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE.","publishingOrg":null,"publicationYear":2026,"doi":"10.1177/03635465251357593","pubmedId":"41476424","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1177/03635465251357593","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1177/03635465251357593","pmid":"41476424","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"f7ec1e98e9c1038e5be22c8bfc284830","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42160466/","evidenceTier":"laboratory","summary":"Regenerative peptides (e.g., body protection compound-157 and thymosin derivatives) and growth hormone axis secretagogues (e.g., CJC-1295, ipamorelin, and tesamorelin) remain investigational, with uncertain safety profiles, product quality concerns, and widespread a …","authors":"Villegas Meza AD, Nocek M, Mitchell BC, Lizarraga M, DeFoor MT, Ruzbarsky JJ, Huard J, Philippon MJ.","publishingOrg":null,"publicationYear":2026,"doi":"10.2106/JBJS.RVW.26.00027","pubmedId":"42160466","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.2106/jbjs.rvw.26.00027","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":63,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":72,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.2106/JBJS.RVW.26.00027","pmid":"42160466","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"061d873f865eb8a714917cf3eef4e8c1","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Peptide Supplements and Their Therapeutic Applications in Sports Medicine.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42578445/","evidenceTier":"laboratory","summary":"PURPOSE: To summarize existing peer-reviewed data on 6 emerging peptides (BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu [copper peptide]) for musculoskeletal recovery and enhancement in animal and human models. ...METHODS: Three indepe …","authors":"Tewari K, Liu TP, Im C, Hamad C, Petrigliano F, Cheung EC, Kremen TJ Jr.","publishingOrg":null,"publicationYear":2026,"doi":"10.1177/03635465261464420","pubmedId":"42578445","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Peptide Supplements and Their Therapeutic Applications in Sports Medicine.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1177/03635465261464420","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":63,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":72,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1177/03635465261464420","pmid":"42578445","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"f78a4b08d5ffba0876d0f2f2e91a5dbe","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41966639/","evidenceTier":"phase_1_2","summary":"Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (anti-obesity drug 9604), BPC-157 (body protection compound 157), CJC-1295 …","authors":"Mendias CL, Awan TM.","publishingOrg":null,"publicationYear":2026,"doi":"10.1007/s40279-026-02437-0","pubmedId":"41966639","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes human_interventional evidence concerning Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.","supportNature":"contextualizes","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s40279-026-02437-0","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"human_interventional","extractionPayload":{"limitations":["Compound-specific human evidence remains limited in size, duration, outcomes, or replication."],"studyDesign":"Human interventional or clinical study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"B","score":74,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":68,"populationRelevance":78},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1007/s40279-026-02437-0","pmid":"41966639","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"4e955355fcb959d2ff4e6b9bc21e02d5","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42123471/","evidenceTier":"laboratory","summary":"This peer-reviewed source examines Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.","authors":"Renke G, Chinellato L.","publishingOrg":null,"publicationYear":2026,"doi":"10.3390/ijms27093890","pubmedId":"42123471","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.","supportNature":"contextualizes","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.3390/ijms27093890","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"D","score":49,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":45,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"provenancePayload":{"doi":"10.3390/ijms27093890","pmid":"42123471","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"1c7bb463282815b0c017a2eddc39d786","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41490200/","evidenceTier":"laboratory","summary":"Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation, whereas growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 activ …","authors":"Rahman OF, Lee SJ, Seeds WA.","publishingOrg":null,"publicationYear":2026,"doi":"10.5435/JAAOSGlobal-D-25-00236","pubmedId":"41490200","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.5435/jaaosglobal-d-25-00236","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.5435/JAAOSGlobal-D-25-00236","pmid":"41490200","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"17f5c8d9f14eee8ac95a1f2f5bc09ef4","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/38197510/","evidenceTier":"laboratory","summary":"With urine samples representing still the most frequently collected doping control specimens, efficient extraction of peptidic analytes from this matrix was a major goal of this method, as demonstrated for the included compounds such as insulins (human, lispro, aspart, glulisine, …","authors":"Thomas A, Walpurgis K, Thevis M.","publishingOrg":null,"publicationYear":2024,"doi":"10.1002/jms.4996","pubmedId":"38197510","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.","supportNature":"contextualizes","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1002/jms.4996","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"D","score":49,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":45,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"provenancePayload":{"doi":"10.1002/jms.4996","pmid":"38197510","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"15f6fa05e141f74ff5b7b993e514d6c0","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/37806509/","evidenceTier":"laboratory","summary":"The present developed and validated method for some GHRHs (tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)-NH(2), somatorelin) is based on the triple quadrupole UHPLC/MS-MS method with solid phase extraction (SPE) with weak cation exchange and is abl …","authors":"Cristea CD, Radu M, Toboc A, Stan C, David V.","publishingOrg":null,"publicationYear":2023,"doi":"10.1016/j.ab.2023.115336","pubmedId":"37806509","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.ab.2023.115336","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1016/j.ab.2023.115336","pmid":"37806509","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"94eb016a17c2fab25206e19e6c054820","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/35298973/","evidenceTier":"laboratory","summary":"This work presents an ultrafiltration-based, validated method for the screening and confirmation of prohibited growth hormone-releasing hormone (GHRH) analogues (sermorelin/CJC-1293, sermorelin metabolite, CJC-1295 and tesamorelin) in urine by nanoLC-HRMS/MS. Sample …","authors":"Coppieters G, Deventer K, Polet M, Van Eenoo P, Judák P.","publishingOrg":null,"publicationYear":2022,"doi":"10.1016/j.jpba.2022.114726","pubmedId":"35298973","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.jpba.2022.114726","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1016/j.jpba.2022.114726","pmid":"35298973","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"fa815c53a4dcbfeafad4bf72663bea4c","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/34736642/","evidenceTier":"laboratory","summary":"The affinity profiles of CBD and carboxy-THC are significantly different from the profiles of synthetic GHR mimetics such as CJC-1295 or [D-Arg(1)-D-Phe(5)-D-Trp(7,9)-Leu(11)]-Substance P peptides, which are the most common interferents; the cannabinoids promoted th …","authors":"Danila GM, Puiu M, Zamfir LG, Bala C.","publishingOrg":null,"publicationYear":2022,"doi":"10.1016/j.talanta.2021.122905","pubmedId":"34736642","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.talanta.2021.122905","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1016/j.talanta.2021.122905","pmid":"34736642","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"982876e347f4e6171b48baa88374216a","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Probing for peptidic drugs (2-10 kDa) in doping control blood samples.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/38716080/","evidenceTier":"laboratory","summary":"Co-extraction and analysis of several different peptides such as insulins (human, lispro, aspart, glulisine, tresiba, detemir, glargine, bovine insulin and porcine insulin), growth hormone releasing hormones (sermorelin, CJC-1295 and tesamorelin), insulin-like growt …","authors":"Thomas A, Thilmany S, Hofmann A, Thevis M.","publishingOrg":null,"publicationYear":2022,"doi":"10.1002/ansa.202200027","pubmedId":"38716080","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Probing for peptidic drugs (2-10 kDa) in doping control blood samples.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1002/ansa.202200027","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1002/ansa.202200027","pmid":"38716080","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"7ac6cf724a807188fa7ea480d48afea9","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Advances in the detection of growth hormone releasing hormone synthetic analogs.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/34665524/","evidenceTier":"laboratory","summary":"This study investigates the in vitro metabolism and detection of four of the larger GHRH synthetic analogs (sermorelin, tesamorelin, CJC-1295, and CJC-1295 with drug affinity complex) in fortified urine. Nineteen major in vitro metabolites were identif …","authors":"Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V.","publishingOrg":null,"publicationYear":2021,"doi":"10.1002/dta.3183","pubmedId":"34665524","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes in_vitro evidence concerning Advances in the detection of growth hormone releasing hormone synthetic analogs.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1002/dta.3183","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"in_vitro","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"In-vitro study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":58,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":18},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1002/dta.3183","pmid":"34665524","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"91df8ada3cf1624181525b250e297c1a","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/32971474/","evidenceTier":"laboratory","summary":"Growth hormone-releasing hormone and its analogues sermorelin, tesamorelin and CJC-1295 are included in the prohibited list of the World Antidoping Agency. These target peptides are found at very low concentrations in urine (at the pg/mL level). ...","authors":"Pont L, Alechaga É, Terrero A, Monfort N, Ventura R.","publishingOrg":null,"publicationYear":2020,"doi":"10.1016/j.chroma.2020.461548","pubmedId":"32971474","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.chroma.2020.461548","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1016/j.chroma.2020.461548","pmid":"32971474","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"0bddfa92894dcf311ccc2d0e65c61148","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/30938069/","evidenceTier":"laboratory","summary":"CJC-1295 is a peptide-based drug that stimulates the production of growth hormone (GH) from the pituitary gland. ...Previously we described a screening procedure for the detection of CJC-1295 in equine plasma using an immuno-PCR assay. Here we demonstr …","authors":"Timms M, Ganio K, Steel R.","publishingOrg":null,"publicationYear":2019,"doi":"10.1002/dta.2599","pubmedId":"30938069","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1002/dta.2599","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1002/dta.2599","pmid":"30938069","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"5b6f592e5886e53dd2611c593640a751","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/30489688/","evidenceTier":"laboratory","summary":"CJC-1295 is a 30 amino acid peptide-based drug that stimulates the release of growth hormone (GH) from the pituitary gland. ...Using a pair of monoclonal antibodies raised against the CJC-1295 peptide, we present an immuno-polymerase chain reaction (I- …","authors":"Timms M, Ganio K, Forbes G, Bailey S, Steel R.","publishingOrg":null,"publicationYear":2019,"doi":"10.1002/dta.2554","pubmedId":"30489688","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1002/dta.2554","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1002/dta.2554","pmid":"30489688","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"617d51d5075d8abc3c43e0051d9ead5a","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/26771670/","evidenceTier":"laboratory","summary":"METHODS: A systematic Internet search was conducted using variation of the term \"CJC-1295\"; and combined with \"forum.\" Ninety-six hits related to bodybuilding websites where CJC-1295 was mentioned. ...These were searched internally for reference to …","authors":"Van Hout MC, Hearne E.","publishingOrg":null,"publicationYear":2016,"doi":"10.3109/10826084.2015.1082595","pubmedId":"26771670","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.3109/10826084.2015.1082595","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.3109/10826084.2015.1082595","pmid":"26771670","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"7287114d58966535a466ee48920951bd","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/26879649/","evidenceTier":"observational","summary":"The target analytes included Geref (Sermorelin), CJC-1293, CJC-1295, and Egrifta (Tesamorelin) as well as two metabolites of Geref and CJC-1293, which were captured from plasma samples using a polyclonal GHRH antibody in concert with protein A/G monolithic MSIA D.A …","authors":"Knoop A, Thomas A, Fichant E, Delahaut P, Schänzer W, Thevis M.","publishingOrg":null,"publicationYear":2016,"doi":"10.1007/s00216-016-9377-3","pubmedId":"26879649","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes human_observational evidence concerning Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.","supportNature":"contextualizes","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s00216-016-9377-3","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"human_observational","extractionPayload":{"limitations":["Compound-specific human evidence remains limited in size, duration, outcomes, or replication."],"studyDesign":"Human observational study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"B","score":70,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":56,"populationRelevance":72},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1007/s00216-016-9377-3","pmid":"26879649","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"19b1d4793d000c85461c7b2ef6acc26c","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"The study of doping market: How to produce intelligence from Internet forums.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/27710891/","evidenceTier":"laboratory","summary":"A temporal analysis illustrates the stability of the most popular products as well as the emergence of new products such as peptides (e.g. CJC-1295). 327 suppliers were detected, mostly with dedicated websites or direct sales by e-mail as selling methods. ...","authors":"Pineau T, Schopfer A, Grossrieder L, Broséus J, Esseiva P, Rossy Q.","publishingOrg":null,"publicationYear":2016,"doi":"10.1016/j.forsciint.2016.09.017","pubmedId":"27710891","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning The study of doping market: How to produce intelligence from Internet forums.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.forsciint.2016.09.017","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1016/j.forsciint.2016.09.017","pmid":"27710891","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"046847df4066eabb1da5dc990d28b084","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/26382721/","evidenceTier":"laboratory","summary":"Such peptides have been used to manipulate several potential performance-enhancing processes in the athlete's body and include for example growth hormone releasing hormones (sermorelin, CJC-1293, CJC-1295, tesamorelin), synthetic/animal insulins (lispro, aspart, glu …","authors":"Thomas A, Walpurgis K, Tretzel L, Brinkkötter P, Fichant E, Delahaut P, Schänzer W, Thevis M.","publishingOrg":null,"publicationYear":2015,"doi":"10.1002/dta.1868","pubmedId":"26382721","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1002/dta.1868","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1002/dta.1868","pmid":"26382721","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"3d778a34d95451d0a9ac1db3d863b295","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/19386527/","evidenceTier":"laboratory","summary":"Serum GH and IGF-1 levels have been shown to increase with administration of GHRH or CJC-1295, a long-acting GHRH analog. DESIGN: Sera from 11 healthy young adult men before and one week after CJC-1295 injection were analyze …","authors":"Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ.","publishingOrg":null,"publicationYear":2009,"doi":"10.1016/j.ghir.2009.03.001","pubmedId":"19386527","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.ghir.2009.03.001","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1016/j.ghir.2009.03.001","pmid":"19386527","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"55015a8f14518138b6d37b4dcfceaece","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/16822960/","evidenceTier":"animal","summary":"We report the effects of CJC-1295 administration in GHRHKO animals. Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 microg of CJC-1295 at intervals of 24, 48, and 72 h. ...These findings demonstrate that treatment with once-daily admi …","authors":"Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R.","publishingOrg":null,"publicationYear":2006,"doi":"10.1152/ajpendo.00201.2006","pubmedId":"16822960","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes animal_in_vivo evidence concerning Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1152/ajpendo.00201.2006","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"animal_in_vivo","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Animal in-vivo study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":46,"populationRelevance":25},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1152/ajpendo.00201.2006","pmid":"16822960","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"ff8830aabe3038615e66d644ef69ad81","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/16352683/","evidenceTier":"phase_1_2","summary":"OBJECTIVE: The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog. DESIGN: The study design was two randomized, placebo-controlled, double-blind, …","authors":"Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA.","publishingOrg":null,"publicationYear":2006,"doi":"10.1210/jc.2005-1536","pubmedId":"16352683","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes human_interventional evidence concerning Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.","supportNature":"contextualizes","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1210/jc.2005-1536","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"human_interventional","extractionPayload":{"limitations":["Compound-specific human evidence remains limited in size, duration, outcomes, or replication."],"studyDesign":"Human interventional or clinical study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"B","score":74,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":68,"populationRelevance":78},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1210/jc.2005-1536","pmid":"16352683","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"9ce076d1d24cd578785938f9475af295","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","title":"Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/17018654/","evidenceTier":"laboratory","summary":"OBJECTIVE: Our objective was to assess GH pulsatility after a single injection of CJC-1295 and determine which GH secretion parameters correlated to the increase in IGF-I production. METHODS: GH pulsatility was assessed by 20-min blood sampling during an overnight 1 …","authors":"Ionescu M, Frohman LA.","publishingOrg":null,"publicationYear":2006,"doi":"10.1210/jc.2006-1702","pubmedId":"17018654","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1210/jc.2006-1702","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:cjc-1295:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1210/jc.2006-1702","pmid":"17018654","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"}],"regulatory":[{"id":"ea0587582d7f4ed2d818c3bc1efbfcbf","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","jurisdiction":"European Union (EMA)","status":"not_approved","approvedIndication":"No centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026.","rationale":"This is a time-bounded review of central EU authorization and does not replace member-state, clinical-trial, pharmacy-compounding, or sports-regulation analysis.","sourceTitle":"European Medicines Agency medicines database","sourceUrl":"https://www.ema.europa.eu/en/medicines","dateChecked":"2026-09-08T19:33:45.384Z","reviewDueAt":"2026-12-07T19:33:45.384Z","enteredById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"77dfb35f628a4b851e98d561b9019a4b","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","jurisdiction":"United States (FDA)","status":"not_approved","approvedIndication":"No FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026.","rationale":"This is a time-bounded database review, not a conclusion about efficacy, safety, compounding law, or approval in another jurisdiction.","sourceTitle":"Drugs@FDA: FDA-Approved Drugs","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/","dateChecked":"2026-09-08T19:33:45.384Z","reviewDueAt":"2026-12-07T19:33:45.384Z","enteredById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"}],"claims":[{"id":"50aedcc520c14fdf218ce50504888666","claimKey":"cjc-1295:source:26771670","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"8511410e77805bcaffc4234d6114e31f","claimId":"50aedcc520c14fdf218ce50504888666","evidenceId":"617d51d5075d8abc3c43e0051d9ead5a","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 26771670","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"d2ea329ed1342669c9277b200029f2d6","claimKey":"cjc-1295:source:41476424","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"d1de526410f0cc87e214a37ad1de86ea","claimId":"d2ea329ed1342669c9277b200029f2d6","evidenceId":"71bb74b360621244e8bddde3eeb0e985","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 41476424","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"fb2f09bafc6aa41852dafb15777661ec","claimKey":"cjc-1295:source:16352683","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes human_interventional evidence concerning Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.","scope":{"evidenceLane":"human_interventional","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","sourceStrengthGrade":"B","sourceStrengthScore":74,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"f92b81d63017e9ca25b79cb5341100cb","claimId":"fb2f09bafc6aa41852dafb15777661ec","evidenceId":"ff8830aabe3038615e66d644ef69ad81","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 16352683","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"4c5b47deb06ce93eef7c46cb9608d056","claimKey":"cjc-1295:source:41880199","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":63,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"6b4f335b9f6b4a6c20abef14a82eb2e9","claimId":"4c5b47deb06ce93eef7c46cb9608d056","evidenceId":"7d0bbf3915cb2ca2c611f21a24803097","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 41880199","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"9414b8f9cb4e1b8b054758863ef7e864","claimKey":"cjc-1295:source:41490200","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"d03f0acc74757d15ed271fef0982c528","claimId":"9414b8f9cb4e1b8b054758863ef7e864","evidenceId":"1c7bb463282815b0c017a2eddc39d786","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 41490200","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"b7901ead215518c56a4d0c57266f4c1c","claimKey":"cjc-1295:source:34665524","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes in_vitro evidence concerning Advances in the detection of growth hormone releasing hormone synthetic analogs.","scope":{"evidenceLane":"in_vitro","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":58,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"af4c99bb341a29b11096162ea0a4ffb3","claimId":"b7901ead215518c56a4d0c57266f4c1c","evidenceId":"7ac6cf724a807188fa7ea480d48afea9","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 34665524","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"4fcefe8b3e4633d84eb8243c2c7b2153","claimKey":"cjc-1295:source:41966639","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes human_interventional evidence concerning Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.","scope":{"evidenceLane":"human_interventional","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","sourceStrengthGrade":"B","sourceStrengthScore":74,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"53866f833bb602c3123e34b4f38eceda","claimId":"4fcefe8b3e4633d84eb8243c2c7b2153","evidenceId":"f78a4b08d5ffba0876d0f2f2e91a5dbe","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 41966639","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"18dd69bdb2141be82b1dd804552b5fb4","claimKey":"cjc-1295:source:19386527","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"5aa79887908e15259412a15230515ee6","claimId":"18dd69bdb2141be82b1dd804552b5fb4","evidenceId":"3d778a34d95451d0a9ac1db3d863b295","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 19386527","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"63b3df56cd999311522963e914d3ff23","claimKey":"cjc-1295:source:42578445","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning Peptide Supplements and Their Therapeutic Applications in Sports Medicine.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":63,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"631f6c98510b9216b8794380a7d6de88","claimId":"63b3df56cd999311522963e914d3ff23","evidenceId":"061d873f865eb8a714917cf3eef4e8c1","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 42578445","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"3a32381fe48ca056e631ca901801a034","claimKey":"cjc-1295:source:42160466","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":63,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"4784e63d402c6f757f85f8c6c8676c3b","claimId":"3a32381fe48ca056e631ca901801a034","evidenceId":"f7ec1e98e9c1038e5be22c8bfc284830","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 42160466","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"91afdb7da606948383d7e9fa33ee12ef","claimKey":"cjc-1295:source:42123471","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.","scope":{"evidenceLane":"mechanistic","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","sourceStrengthGrade":"D","sourceStrengthScore":49,"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"dc15797723c7fa5c3eac94dc86f7d87b","claimId":"91afdb7da606948383d7e9fa33ee12ef","evidenceId":"4e955355fcb959d2ff4e6b9bc21e02d5","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 42123471","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"f2a0e049ab40b58417f4055494fac6fa","claimKey":"cjc-1295:source:16822960","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes animal_in_vivo evidence concerning Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.","scope":{"evidenceLane":"animal_in_vivo","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"0c524bec1dbb5d0c77d18731cf5d503e","claimId":"f2a0e049ab40b58417f4055494fac6fa","evidenceId":"55015a8f14518138b6d37b4dcfceaece","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 16822960","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"0de620b4d5f5050c33cfb8dde53a9852","claimKey":"cjc-1295:source:38716080","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning Probing for peptidic drugs (2-10 kDa) in doping control blood samples.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"32fec3e98f403c5a8d916a0b51ba1043","claimId":"0de620b4d5f5050c33cfb8dde53a9852","evidenceId":"982876e347f4e6171b48baa88374216a","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 38716080","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"2f3bb9b6fd85e2adbff289f0705162d2","claimKey":"cjc-1295:source:38197510","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.","scope":{"evidenceLane":"mechanistic","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","sourceStrengthGrade":"D","sourceStrengthScore":49,"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"c838e0e489b74d4aa00c96777f7727e3","claimId":"2f3bb9b6fd85e2adbff289f0705162d2","evidenceId":"17f5c8d9f14eee8ac95a1f2f5bc09ef4","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 38197510","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"ee29e4d3b166ab3c0c88e11b613f6b98","claimKey":"cjc-1295:source:30938069","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"406a5ea1cc5d8ac897f28ca84da7a600","claimId":"ee29e4d3b166ab3c0c88e11b613f6b98","evidenceId":"0bddfa92894dcf311ccc2d0e65c61148","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 30938069","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"d65672b050ab4ad472960467a4ff2219","claimKey":"cjc-1295:source:27710891","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning The study of doping market: How to produce intelligence from Internet forums.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"d4093ce679935e38723f325bab7bd161","claimId":"d65672b050ab4ad472960467a4ff2219","evidenceId":"19b1d4793d000c85461c7b2ef6acc26c","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 27710891","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"e55abb1ae8cb602ba3fd61c252d53698","claimKey":"cjc-1295:source:41138283","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"fb45ab8c1bfe45d7f023338fb35ebd9d","claimId":"e55abb1ae8cb602ba3fd61c252d53698","evidenceId":"ad52c44ac4882176bfce1b1c6379434d","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 41138283","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"a14eba1215ec57f5311f2c229af7a9b4","claimKey":"cjc-1295:source:17018654","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"302ab74030b436d7e10bc7a459af5425","claimId":"a14eba1215ec57f5311f2c229af7a9b4","evidenceId":"9ce076d1d24cd578785938f9475af295","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 17018654","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"5647f14b7cde00ed7a6b55a91ddf5419","claimKey":"cjc-1295:source:37806509","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"01f9b41e5b9c29759569238130dbe821","claimId":"5647f14b7cde00ed7a6b55a91ddf5419","evidenceId":"15f6fa05e141f74ff5b7b993e514d6c0","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 37806509","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"1c9f3e6e284a3b17d331903f7968318b","claimKey":"cjc-1295:source:34736642","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"5dd5f2e135dbb130c8be7b2a7c85a4ca","claimId":"1c9f3e6e284a3b17d331903f7968318b","evidenceId":"fa815c53a4dcbfeafad4bf72663bea4c","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 34736642","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"56dbe3cd165f610a2b03c51ff55d9be3","claimKey":"cjc-1295:source:30489688","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"a3348227f705c664a1b30654790c8422","claimId":"56dbe3cd165f610a2b03c51ff55d9be3","evidenceId":"5b6f592e5886e53dd2611c593640a751","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 30489688","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"2d94c5de24ae1b87b641b3bae72eaa35","claimKey":"cjc-1295:source:26879649","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes human_observational evidence concerning Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.","scope":{"evidenceLane":"human_observational","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","sourceStrengthGrade":"B","sourceStrengthScore":70,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"92389a5fff231b0e6e387497fc40e26c","claimId":"2d94c5de24ae1b87b641b3bae72eaa35","evidenceId":"7287114d58966535a466ee48920951bd","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 26879649","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"feb5bd5adbfd7cd92b430817098342db","claimKey":"cjc-1295:source:26382721","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"65244360392902e5ddfd42eaa0eec4d5","claimId":"feb5bd5adbfd7cd92b430817098342db","evidenceId":"046847df4066eabb1da5dc990d28b084","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 26382721","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"aab8a9d1590caaf88055b61355b0116d","claimKey":"cjc-1295:source:35298973","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"d0eb1949a144849c5a193eb1b8b82637","claimId":"aab8a9d1590caaf88055b61355b0116d","evidenceId":"94eb016a17c2fab25206e19e6c054820","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 35298973","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"0fbd2ad618ab9277d3a49697c016103a","claimKey":"cjc-1295:source:32971474","peptideId":"b6eac7dd-9ae2-4b2c-86e8-0ba95f48c9ee","claimText":"This source contributes mechanistic evidence concerning Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"0c7b71fc38e485475f476271255eda9d","claimId":"0fbd2ad618ab9277d3a49697c016103a","evidenceId":"91df8ada3cf1624181525b250e297c1a","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 32971474","createdAt":"2026-09-08T19:33:45.384Z"}]}],"correctionHistory":[],"boundaries":{"observationsAreEvidence":false,"completionIsPublicationApproval":false,"medicalAdvice":false}}